Eli Lilly ( LLY 1.32%) is now known for its weight loss drugs. Its stock has risen 150% since mid-2022 because of high demand for Mounjaro (tirzepatide approved to treat type 2 diabetes) and Zepbound ...

Eli Lilly’s new GLP-1 drug and diversified R&D pipeline could drive healthcare sector inflows and deliver over 40% upside.

Eli Lilly And Company ((LLY)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst ...

Four American families are desperate to save their children from a devastating genetic disease. The cure exists — but it’s up to them to raise $1.15 million to fund a clinical trial. Each of these ...

Treatments and Long Recovery Process Bella Hadid’s treatment and recovery journey has been anything but simple. Over the past few years, she has undergone more than 100 days of intensive therapies to ...

Roche targets liver disease treatments with acquisition Deal includes $14.50 a share, potential milestone payments up to $6.00 a share Roche flags potential to treat obesity-related conditions The ...

Yolanda Hadid is by her daughter Bella Hadid’s side as the model battles a flare-up of her chronic neurological Lyme disease. Yolanda, 61, shared a touching message about Bella’s “courageous” fight ...

NEW YORK – Faeth Therapeutics has added a small molecule drug to its therapeutic pipeline, which it hopes will address both the genetic drivers and the metabolic processes underlying two rare diseases ...

BOSTON, Sept. 17, 2025 /PRNewswire/ -- Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies designed to modulate critical RNA targets, today ...

The FDA may fast-track Eli Lilly's experimental weight-loss pill, orforglipron, potentially adding $1 billion in early revenue. This aligns with the Trump Administration's goals to reduce drug prices.